HOME SITE MAP SEARCH
About Us News Distributors Venofer Injectafer Contract Manufacturing Grant Requests and Investigator Sponsored Trials Jobs Contact Us
PRODUCT CATALOG
All Products
Therapeutic Injectable, Electrolytes & IV Additives
Multiple Trace Element Additives
Multiple Electrolyte Additives
Single Entity Trace Elements
Inhalation & Oral Solutions
Ophthalmics & Otics
Diuretics
Products with vial closures that are not made with natural rubber latex
Preservative Free Products
Product Search
Product Availability
Return Goods Policy
Sales Policy
Vial Closure Information

Cyanocobalamin Injection, USP

Prescribing Info SDS/MSDS
NDC # 0517-0031-25
Description 1000 mcg/mL
(Preserved with 1.5% Benzyl Alcohol)
(Vial closure is not made with natural rubber latex)
Supplied 1 mL Vial
Shelf Pack 25
Wholesaler Numbers
AmerisourceBergen Item #: 031765
Cardinal Item #: 2529212
HD Smith Item #: 1073931
McKesson Item #: 1310242
Morris & Dickson Co. Item #: 780171
NDC # 0517-0032-25
Description 1000 mcg/mL
(Preserved with 1.5% Benzyl Alcohol)
(Vial closure is not made with natural rubber latex)
Supplied 10 mL Multiple Dose Vial
Shelf Pack 25
Wholesaler Numbers
AmerisourceBergen Item #: 561076
Cardinal Item #: 1193689
HD Smith Item #: 5171020
McKesson Item #: 1621986
Morris & Dickson Co. Item #: 104752
NDC # 0517-0130-05
Description 1000 mcg/mL
(Preserved with 1.5% Benzyl Alcohol)
(Vial closure is not made with natural rubber latex)
Supplied 30 mL Multiple Dose Vial
Shelf Pack 5
Wholesaler Numbers
AmerisourceBergen Item #: 746949
Cardinal Item #: 3453719
HD Smith Item #: 1459486
McKesson Item #: 1984673
Morris & Dickson Co. Item #: 476101
DAIICHI SANKYO NAMES NEW PRESIDENT OF US SUBSIDIARY LUITPOLD PHARMACEUTICALS, INC.

June 29, 2016 – Effective today, Ken Keller has been newly appointed as President and CEO of Luitpold Pharmaceuticals, in addition to his current position as President, Daiichi Sankyo Administrative and Commercial, Daiichi Sankyo, Inc.

With more than 25 years of experience in the pharmaceutical industry in commercial leadership and joint venture leadership, Mr. Keller will now oversee both the Daiichi Sankyo, Inc. Commercial organization and Luitpold Pharmaceuticals, Inc.

Mr. Keller joined Daiichi Sankyo, Inc. in 2014 and has also served on the Luitpold Board of Directors since 2015. He has successfully led the Daiichi Sankyo, Inc. US commercial organization as it begins its transformation to a specialty focused company.

“While Luitpold and Daiichi Sankyo US businesses serve different customers and markets, they each bring to the table important strengths and focus that are essential to the continued success and growth of the Daiichi Sankyo Group,” said Ken Keller. “I look forward to working with the Luitpold team and driving even further success in the future.”

Luitpold Pharmaceuticals, Inc. is a Daiichi Sankyo Group Company headquartered in Shirley, NY, and manufactures more than 80 pharmaceutical products.